Clearside Biomedical Statistics
Total Valuation
CLSD has a market cap or net worth of $34.94 million. The enterprise value is $81.80 million.
Important Dates
The next estimated earnings date is Tuesday, August 26, 2025, after market close.
| Earnings Date | Aug 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CLSD has 78.51 million shares outstanding. The number of shares has increased by 13.54% in one year.
| Current Share Class | 78.51M |
| Shares Outstanding | 78.51M |
| Shares Change (YoY) | +13.54% |
| Shares Change (QoQ) | +1.20% |
| Owned by Insiders (%) | 13.24% |
| Owned by Institutions (%) | 14.96% |
| Float | 68.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.16 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 19.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.87
| Current Ratio | 3.87 |
| Quick Ratio | 3.34 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.09 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -55.45% |
| Return on Invested Capital (ROIC) | -101.90% |
| Return on Capital Employed (ROCE) | -177.91% |
| Revenue Per Employee | $130,188 |
| Profits Per Employee | -$866,031 |
| Employee Count | 32 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CLSD has paid $715,000 in taxes.
| Income Tax | 715,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.41% in the last 52 weeks. The beta is 2.09, so CLSD's price volatility has been higher than the market average.
| Beta (5Y) | 2.09 |
| 52-Week Price Change | -58.41% |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 0.88 |
| Relative Strength Index (RSI) | 41.80 |
| Average Volume (20 Days) | 13,232,078 |
Short Selling Information
The latest short interest is 1.98 million, so 2.52% of the outstanding shares have been sold short.
| Short Interest | 1.98M |
| Short Previous Month | 162,565 |
| Short % of Shares Out | 2.52% |
| Short % of Float | 2.90% |
| Short Ratio (days to cover) | 0.89 |
Income Statement
In the last 12 months, CLSD had revenue of $4.17 million and -$27.71 million in losses. Loss per share was -$0.36.
| Revenue | 4.17M |
| Gross Profit | 3.77M |
| Operating Income | -21.86M |
| Pretax Income | -34.97M |
| Net Income | -27.71M |
| EBITDA | -21.53M |
| EBIT | -21.86M |
| Loss Per Share | -$0.36 |
Full Income StatementBalance Sheet
The company has $9.38 million in cash and $56.24 million in debt, giving a net cash position of -$46.86 million or -$0.60 per share.
| Cash & Cash Equivalents | 9.38M |
| Total Debt | 56.24M |
| Net Cash | -46.86M |
| Net Cash Per Share | -$0.60 |
| Equity (Book Value) | -48.73M |
| Book Value Per Share | -0.62 |
| Working Capital | 8.74M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$21.73 million and capital expenditures -$506,000, giving a free cash flow of -$22.23 million.
| Operating Cash Flow | -21.73M |
| Capital Expenditures | -506,000 |
| Free Cash Flow | -22.23M |
| FCF Per Share | -$0.28 |
Full Cash Flow StatementMargins
| Gross Margin | 90.47% |
| Operating Margin | -524.63% |
| Pretax Margin | -648.06% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLSD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.54% |
| Shareholder Yield | -13.54% |
| Earnings Yield | -79.32% |
| FCF Yield | -63.63% |
Analyst Forecast
The average price target for CLSD is $4.33, which is 873.03% higher than the current price. The consensus rating is "Hold".
| Price Target | $4.33 |
| Price Target Difference | 873.03% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 144.67% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CLSD has an Altman Z-Score of -36.64 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -36.64 |
| Piotroski F-Score | 1 |